Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 8/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | LMNA | P02545 | 6/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.56 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.56 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.56 |
| ▸ | SHBG | P04278 | 2/20 | 0.56 |
| ▸ | PGR | P06401 | 2/20 | 0.56 |
| ▸ | AR | P10275 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28255051 | 0.95 | CYP3A4 (0.59) | CYP3A4ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL2561836 | 0.93 | CYP3A4 (0.56) | CYP3A4ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL2042111 | 0.93 | CYP3A4 (0.58) | CYP3A4ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL11023737 | 0.91 | CYP3A4 (0.60) | CYP3A4ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL28137569 | 0.90 | CYP3A4 (0.54) | CYP3A4ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL571724 | 0.90 | LMNA (0.62) | CYP3A4ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL5331 | 0.90 | LMNA (0.62) | CYP3A4ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL571134 | 0.90 | CYP19A1 (0.61) | CYP3A4ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL5425553 | 0.90 | LMNA (0.64) | CYP3A4ALDH1A1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL353517 | 0.90 | LMNA (0.64) | CYP3A4ALDH1A1LMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1862167-A2 | Methods and formulations for the treatment of female sexual dysfunction | Barr Laboratories, Inc. (US) | 2007-12-05 | — | — | EP | claimed |
| EP-1848541-A2 | METHOD AND DEVICE FOR OPHTHALMIC ADMINISTRATION OF ACTIVE PHARMACEUTICAL INGREDIENTS | Pharmalight Inc. (US) | 2007-10-31 | — | — | EP | claimed |
| EP-1359920-B1 | USES OF ORAL FORMULATIONS FOR THE TREATMENT OF FEMALE SEXUAL DYSFUNCTION | BARR LAB INC (US) | 2007-08-22 | — | — | EP | claimed |
| WO-2006082588-A2 | METHOD AND DEVICE FOR OPHTHALMIC ADMINISTRATION OF ACTIVE PHARMACEUTICAL INGREDIENTS | PHARMALIGHT INC. (US) | 2006-08-10 | — | — | WO | claimed |
| US-20050042268-A1 | Pharmaceutical composition and method for transdermal drug delivery | PERRIGO ISRAEL PHARMACEUTICALS LTD. (IL) | 2005-02-24 | — | — | US | claimed |
| US-20050025833-A1 | Pharmaceutical composition and method for transdermal drug delivery | PERRIGO ISRAEL PHARMACEUTICALS LTD. (IL) | 2005-02-03 | — | — | US | claimed |
| US-20050020552-A1 | Pharmaceutical composition and method for transdermal drug delivery | PERRIGO ISRAEL PHARMACEUTICALS LTD. (IL) | 2005-01-27 | — | — | US | claimed |
| US-20040259817-A1 | Methods and formulations for the treatment of female sexual dysfunction | BARR LABORATORIES, INC. | 2004-12-23 | — | — | US | claimed |
| EP-1359920-A2 | METHODS AND FORMULATIONS FOR THE TREATMENT OF FEMALE SEXUAL DYSFUNCTION | Endeavor Pharmaceuticals (US) | 2003-11-12 | — | — | EP | claimed |
| US-20020107230-A1 | Methods and formulations for the treatment of female sexual dysfunction | BARR LABORATORIES, INC. | 2002-08-08 | — | — | US | claimed |
| WO-2002051420-A2 | METHODS AND FORMULATIONS FOR THE TREATMENT OF FEMALE SEXUAL DYSFUNCTION | ENDEAVOR PHARMACEUTICALS (US) | 2002-07-04 | — | — | WO | claimed |
| US-20190091149-A1 | Oil foamable carriers and formulations | FOAMIX PHARMACEUTICALS LTD. | 2019-03-28 | — | — | US | disclosed |
| EP-2826371-B1 | Methods and compositions for inhibiting integrins using tellurium-containing compounds | FERAMDA LTD (IL) | 2019-01-02 | — | — | EP | disclosed |
| US-20180133149-A1 | DRUG-DELIVERING COMPOSITE STRUCTURES | ZILBERMAN, MEITAL (IL) | 2018-05-17 | — | — | US | disclosed |
| US-20170348418-A1 | Foamable Vehicle and Pharmaceutical Compositions Thereof | FOAMIX PHARMACEUTICALS, LTD. (IL) | 2017-12-07 | — | — | US | disclosed |
| US-20050020552-A1 | Pharmaceutical composition and method for transdermal drug delivery | PERRIGO ISRAEL PHARMACEUTICALS LTD. (IL) | 2005-01-27 | — | — | US | disclosed |
| US-20040259817-A1 | Methods and formulations for the treatment of female sexual dysfunction | BARR LABORATORIES, INC. | 2004-12-23 | — | — | US | disclosed |
| EP-1359920-A2 | METHODS AND FORMULATIONS FOR THE TREATMENT OF FEMALE SEXUAL DYSFUNCTION | Endeavor Pharmaceuticals (US) | 2003-11-12 | — | — | EP | disclosed |
| US-20020107230-A1 | Methods and formulations for the treatment of female sexual dysfunction | BARR LABORATORIES, INC. | 2002-08-08 | — | — | US | disclosed |
| WO-2002051420-A2 | METHODS AND FORMULATIONS FOR THE TREATMENT OF FEMALE SEXUAL DYSFUNCTION | ENDEAVOR PHARMACEUTICALS (US) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190091149-A1 | Oil foamable carriers and formulations | LIPA, PTGER1, TTPA | CYP3A4 3480/4885ALDH1A1 3782/4885LMNA 500/4885 |
| US-20180133149-A1 | DRUG-DELIVERING COMPOSITE STRUCTURES | PLOD3, NEFM, APMAP | CYP3A4 2006/4885ALDH1A1 1424/4885LMNA 383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.